Thursday , October 19 2017
Home / Letter From The Editor / GLP-1 Analog Special Edition, May 2014

GLP-1 Analog Special Edition, May 2014

Way back in July 2011 we reviewed some of the emerging data showing that the GLP-1 RA class might have some value in improving cardiovascular outcomes. As newer entities in this class have been researched the cardiovascular studies required for approval and aftermarket monitoring continue to show the value of GLP-1 mimetics in improving cardiovascular outcomes. This month I have prepared an update to that report we issued to you back in 2011 and I encourage you to bring yourself up to speed by reviewing this newer data.